A randomised trial of chemotherapy with or without granulocyte colony-stimulating factor (G-CSF) in operable osteosarcoma

Submission date	Recruitment status No longer recruiting	Prospectively registered		
28/02/2001		Protocol		
Registration date	Overall study status	Statistical analysis plan		
28/02/2001	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
11/05/2022	Cancer			

Plain English summary of protocol

http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=107

Contact information

Type(s)

Scientific

Contact name

Dr Barbara Uscinska

Contact details

MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

BO06

Study information

Scientific Title

_

Study objectives

To compare two regimens of chemotherapy using Doxorubicin and Cisplatin in operable osteosarcoma: one involving chemotherapy at three weekly intervals with surgery after two courses, the other, chemotherapy at two weekly intervals plus G-CSF with surgery after three courses.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Osteosarcoma

Interventions

Two regimens of chemotherapy:

- 1. The first is Doxorubicin and Cisplatin at three weekly intervals with surgery after two courses /chemotherapy.
- 2. The second is Doxorubicin and Cisplatin at two weekly intervals plus G-CSF with surgery after three courses.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Doxorubicin and Cisplatin

Primary outcome measure

- 1. Survival time
- 2. Response rate
- 3. Morbidity
- 4. Response duration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/07/1993

Completion date

30/09/2002

Eligibility

Key inclusion criteria

- 1. Untreated non-metastatic disease
- 2. Age less than or equal to 40 years
- 3. Neutrophils \geq 1.5 times 10^9/l and platelets \geq 100 times 10^9/l
- 4. Glomerular Filtration Rate (GFR) ≥60 ml/min/1.73 m^2
- 5. Serum bilirubin ≤ micromoles/L
- 6. Normal cardiac function
- 7. Informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Not Specified

Target number of participants

500

Total final enrolment

497

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/07/1993

Date of final enrolment

30/09/2002

Locations

Countries of recruitment

England

United Kingdom

Study participating centre MRC Clinical Trials Unit London

United Kingdom NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent London United Kingdom W1B 1AL +44 (0)20 7636 5422 clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

http://www.mrc.ac.uk

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/01/2007		Yes	No
Other publications	retrospective analysis	01/05/2019	13/02/2020	Yes	No
Other publications	retrospective analysis	30/05/2019	28/04/2020	Yes	No
Other publications	retrospective analysis	16/12/2021	20/12/2021	Yes	No
Other publications	retrospective reanalysis	10/05/2022	11/05/2022	Yes	No